Patents Assigned to Trubion Pharmaceuticals, Inc.
-
Publication number: 20090148447Abstract: Specific binding peptides having a general schematized structure of an optional N-terminal hinge region joined to an immunoglobulin-derived constant sub-region comprising a CH2 region and a CH3 region, followed by a PIMS linker peptide and at least one specific binding domain are provided, along with encoding nucleic acids, vectors and host cells. Also provided are methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: July 7, 2008Publication date: June 11, 2009Applicant: TRUBION PHARMACEUTICALS, INC.Inventors: Jeffrey A. Ledbetter, William Brady
-
Publication number: 20090041765Abstract: Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.Type: ApplicationFiled: April 11, 2008Publication date: February 12, 2009Applicant: TRUBION PHARMACEUTICALS, INC.Inventors: Erik S. Espling, Peter A. Thompson, Peter R. Baum
-
Publication number: 20080279850Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.Type: ApplicationFiled: April 11, 2008Publication date: November 13, 2008Applicant: TRUBION PHARMACEUTICALS, INC.Inventors: William Brady, Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter, Sandy A. Simon, Peter A. Thompson
-
BINDING PROTEINS COMPRISING IMMUNOGLOBULIN HINGE AND FC REGIONS HAVING ALTERED FC EFFECTOR FUNCTIONS
Publication number: 20080227958Abstract: Provided herein are binding proteins comprising one or more immunoglobulin Fc region hinge, CH2, and/or CH3 domain wherein one or more hinge and/or constant region CH2 and/or CH3 domain is modified to alter the binding protein's binding affinity and/or specificity for a cognate receptor (e.g., an Fc receptor) and/or to impart one or more new binding specificity(ies) to the hinge and/or constant region that the corresponding unmodified immunoglobulin does not possess (e.g., affinity for distinct class of cognate receptor distinct from the class of cognate receptor to which the unmodified binding protein specifically binds). Binding proteins according to the present invention include, for example, modified antibodies, antibody fragments, recombinant binding proteins, and molecularly engineered binding domain-immunoglobulin fusion proteins, including small modular immunopharmaceutical products (SMIP™ products).Type: ApplicationFiled: April 13, 2007Publication date: September 18, 2008Applicant: Trubion Pharmaceuticals Inc.Inventors: Peter Armstrong Thompson, Erik Stephen Espling, Peter Robert Baum, Phillip Tan -
Publication number: 20080213273Abstract: The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity using a single dose of CD20-specific binding molecule.Type: ApplicationFiled: July 25, 2006Publication date: September 4, 2008Applicant: TRUBION PHARMACEUTICALS INC.Inventor: Daniel J. Burge
-
Publication number: 20070059306Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.Type: ApplicationFiled: July 25, 2006Publication date: March 15, 2007Applicant: TRUBION PHARMACEUTICALS, INC.Inventors: Laura Grosmaire, Martha Hayden-Ledbetter, Jeffrey Ledbetter, Peter Thompson, Sandy Simon, William Brady
-
Publication number: 20070021591Abstract: Compositions and methods are provided for achieving the deaggregation of binding proteins including, but not limited to, protein ligands, soluble receptors, antibodies, antibody fragments, variable fragment single-chain antibodies (scFv), and small modular immunopharmaceutical products (SMIP™ products). The compositions, which are suitable for the deaggregation of highly concentrated solutions of binding proteins, contain one or more chaotrope, are typically formulated at an acidic pH, and may be used to provide binding proteins suitable for the preparation of pharmaceutical compositions and administration in vivo to a patient.Type: ApplicationFiled: July 24, 2006Publication date: January 25, 2007Applicant: TRUBION PHARMACEUTICALS, INC.Inventors: Arthur Movius, Rajesh Dua
-
Patent number: 7118751Abstract: Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface receptor are internalized, carrying antigen(s) into an intracellular compartment where the antigen(s) are digested into peptides and loaded onto MHC molecules. T cells specific for the peptide antigens are activated, leading to an enhanced immune response. The vaccine may comprise antigen(s) linked to a domain that binds at least one receptor or a DNA plasmid encoding antigen(s) linked to a domain that binds at least one receptor. A preferred embodiment of the invention targets HIV-1 env antigen to the CD40 receptor, resulting in delivery of antigen to CD40 positive cells, and selective activation of the CD40 receptor on cells presenting HIV-1 env antigens to T cells.Type: GrantFiled: October 13, 2000Date of Patent: October 10, 2006Assignee: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey A Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050238646Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: October 27, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050202534Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: September 15, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050202028Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: September 15, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050202023Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: September 15, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050202012Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: September 15, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050186216Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: August 25, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050180970Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: August 18, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20050175614Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: March 23, 2005Publication date: August 11, 2005Applicant: Trubion Pharmaceuticals, Inc.Inventors: Jeffrey Ledbetter, Martha Hayden-Ledbetter